Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial
about
Targeted therapy of gastrointestinal stromal tumoursTargeting gastrointestinal stromal tumors: the role of regorafenibMolecularly targeted drugs for metastatic colorectal cancerRegorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy ModelsSunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectivesUpdate on clinical research and state of the art management of patients with advanced sarcomas and GISTMicroenvironmental Targets in SarcomaRegorafenib for gastrointestinal malignancies : from preclinical data to clinical results of a novel multi-target inhibitor.Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib.Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access ProgramOptimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care.Targeted therapy for cancer: the gastrointestinal stromal tumor model.Regorafenib: Adding to the Armamentarium for Refractory Colorectal Cancer and GIST.Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review.Regorafenib: an evidence-based review of its potential in patients with advanced liver cancerCYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinibEfficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.A gist of gastrointestinal stromal tumors: A review.Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutationsMultitarget inhibitors derived from crosstalk mechanism involving VEGFR2.Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program.Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists.Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials.Characteristics and prognosis of rectal gastrointestinal stromal tumors: an analysis of registry data.The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations.Pancreatic GIST in a Patient with Limited Stage Small Cell Lung Cancer: A Case Report and Review of Published Cases.Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma.Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies.Optimizing tyrosine kinase inhibitor therapy in gastrointestinal stromal tumors: exploring the benefits of continuous kinase suppression.Drug monographs: bosutinib and regorafenib.Esophageal gastrointestinal stromal tumors presenting as mediastinal massPharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models.Recent advances in the treatment of gastrointestinal stromal tumors.Management of gastrointestinal stromal tumors.Regorafenib: carving a niche in the crowded therapeutic landscape.
P2860
Q26745633-138D5B45-35A9-4E8C-892E-06D9066803C9Q26747162-2CA7EBEA-CA7B-42C2-B3DB-8D79CF0057F5Q26828735-8125A056-27CF-4BAF-94CF-01A4A3A9A774Q27345024-78B98250-131B-49A5-BB88-A0D2649DF971Q28069560-3D3B386B-2390-48BC-B0F6-12629681F598Q28073290-B819A9D0-910A-42BF-B729-729430DDD121Q28081400-6A9A81CE-4D18-4C08-85C6-961C02F8977BQ30593460-FF00309E-738F-48A5-968B-E1F674FC1B30Q33410655-13FED258-4AD2-49E4-B91D-518A903E4FD6Q33584090-969DA9E2-65DE-43CB-9B5D-C7E4E0AF6CC6Q33699635-C99924DA-53C9-45A4-9193-58F2B424E773Q33807742-C4F11554-FCA0-4B3E-88D6-EFBB3F4A9AFEQ33885957-416D1BEB-95C2-4524-A877-0AA80950F7F6Q33895608-0D128441-1F81-4345-B946-9FA101216626Q33944599-AC02070C-9834-4E0D-BE90-94D6854ABD01Q34387852-74373978-B72B-43B9-B513-085E03BD5DA2Q34518436-F443AD6D-97FF-4DCA-92ED-F593374070F8Q34566471-BA30C2F1-B7E7-41DB-81D5-A9D04A57741CQ34645665-F0A810C5-A808-4F9A-B2E2-0598CED46BD3Q34654203-6A2EA326-50B0-4E54-9A0D-FA779A582631Q34662946-DD9732BF-0A2B-4AA5-938E-95E85ED82DA5Q34737119-D9920436-52E9-4DB2-AAD7-064CFD418712Q34804754-9ACCE193-698F-4BC2-B74B-2CEE4D81D88DQ35434188-CD565339-F3AE-492C-B75A-9C2882280385Q35519994-6A942225-4F17-4451-A897-E449CDF1F7AAQ35689747-6FBA21C3-AF00-4F46-AC82-113391B37177Q36078348-07053B64-B21F-4D8F-9CDC-010944C73B1DQ36192000-078B41EA-A5BC-48E1-A1DE-217A78473E67Q36350526-53FA5FA8-8AC5-4F55-9F58-D815190AD30EQ36509363-E9A46C8E-5028-4E5A-AAE5-45FE77ACF65AQ37192877-585C8276-B919-4CDE-BBBB-1D9D9490BAFAQ37211199-8513109F-1766-43FA-A32F-0A66C99C11D0Q37220191-068BE761-8016-43FF-96EB-11069FA31045Q37301465-E8DD2648-3DFD-421E-BF2E-0BE5940B106AQ37340111-2712FF4B-2990-4CB8-9A3A-3DBEA1F2A7DAQ37389277-783CC793-9629-4BC3-8F72-6AF3C9074CF2Q37429966-9BB17998-3258-410C-9F40-34C3235303D8Q37704347-3A45250B-DB0E-49FE-A26E-6C626613FF05Q38081983-4EBD3892-5FDA-4A6D-9D84-9D01AD1E603AQ38096471-0D73F344-973F-45AB-B043-929F4CD0B0DD
P2860
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Efficacy and safety of regoraf ...... : a multicenter phase II trial
@en
type
label
Efficacy and safety of regoraf ...... : a multicenter phase II trial
@en
prefLabel
Efficacy and safety of regoraf ...... : a multicenter phase II trial
@en
P2093
P2860
P921
P356
P1476
Efficacy and safety of regoraf ...... : a multicenter phase II trial
@en
P2093
Andrew J Wagner
Annick D Van den Abbeele
Christopher L Corless
Edwin Choy
George D Demetri
James E Butrynski
Jeffrey A Morgan
Jeffrey T Yap
Jonathan A Fletcher
Judith B Manola
P2860
P304
P356
10.1200/JCO.2011.39.9394
P407
P577
2012-05-21T00:00:00Z